Navigation Links
Pharmaceutical Market Fails to Capture $188 Billion U.S. Revenue and $564 Billion Global Revenue Annually Due to Medication Non-Adherence
Date:11/26/2012

NORWALK, Conn., Nov. 26, 2012 /PRNewswire/ -- Capgemini Consulting, the global strategy and transformation consulting arm of the Capgemini Group, has announced the release of its study conducted with HealthPrize Technologies, "Estimated Annual Pharmaceutical Revenue Loss Due to Medication Non-Adherence." The report provides key insights and analysis on the significant revenue loss to global pharmaceutical companies as a result of medication non-adherence.

Based on detailed review and analysis of modern claims-based adherence literature and data, the estimate of revenue lost by the U.S. pharmaceutical industry each year due to non-adherence to medications for chronic disease is $188 billion. Extrapolated to the global pharmaceutical industry, revenue losses are estimated to be $564 billion. This number is significantly higher than the $30 billion global revenue loss often quoted to date from a 2004 study1, and higher than many pharmaceutical executive estimates. 

This revenue loss represents 59% of all pharmaceutical revenues, which were $320 billion in the U.S. and $956 billion globally in 2011 according to IMS, and 37% of potential total annual revenues, which would be $508 billion in the U.S. and $1,520 billion globally.  While achieving 100% medication adherence is likely not possible, even a modest 10 percentage point increase in adherence could lead to a significant rise in pharmaceutical revenues, accompanied by improved health outcomes and decreased healthcare spending.

"The revenue that pharma leaves on the table due to lack of adherence to prescription medications is much higher than usually thought," explained Thomas Forissier, Principal at Capgemini Consulting. "In addition, many people don't realize that a 10% boost in adherence could increase revenue by much more than 10%. That 10% loss is based on the higher revenue amount that could have materialized, not on actual revenue earned."

"Medication non-adherence is one of the most serious problems in healthcare, posing a heavy financial impact on all constituencies," commented Katrina Firlik, MD, co-founder and chief medical officer of HealthPrize. "For insurers, employers, and patients, non-adherence significantly increases healthcare costs as a result of disease-related complications. For pharmaceutical companies, pharmacies, and pharmacy benefits managers, non-adherence significantly erodes profit due to prescriptions never filled and medications not taken often enough.  Given the significant potential to enhance revenue and lower cost to the overall healthcare system, programs to address medication adherence should be a top priority to the pharmaceutical industry."

Report Highlights:

  • The U.S. pharmaceutical industry loses an estimated $188 billion annually due to medication non-adherence. This represents 59% of the $320 billion in total U.S. pharmaceutical revenues in 2011.
  • Global pharmaceutical revenue loss is estimated to be $564 billion, or 59% of the $956 billion in total global pharmaceutical revenues in 2011.
  • Medication non-adherence is a problem across almost all chronic conditions, not only for primary care conditions such as diabetes, hypertension, and high cholesterol, but also for such serious conditions as HIV, oncology, transplant, and glaucoma.
  • In the U.S. diabetes market alone, revenue loss is estimated to be $11.4 billion.

Report Access:

To download a full copy of "Annual Pharmaceutical Revenue Loss Due to Medication Non-Adherence," please go to http://www.capgemini-consulting.com/think/publication_detail/?id=CA4F0A5C-FC61-D872-3853-C4C97324D41E&type=document. The report is also available on http://www.adherence564.com/ with key study findings and a central forum for discussion.

About Capgemini Consulting:

Capgemini Consulting is the global strategy and transformation consulting organization of the Capgemini Group, specializing in advising and supporting enterprises in significant transformation, from innovative strategy to execution and with an unstinting focus on results. With the new digital economy creating significant disruptions and opportunities, our global team of over 3,600 talented individuals work with leading companies and governments to master Digital Transformation, drawing on our understanding of the digital economy and our leadership in business transformation and organizational change.

Find out more at: http://www.capgemini-consulting.com/

About Capgemini:

With more than 120,000 people in 40 countries, Capgemini is one of the world's foremost providers of consulting, technology and outsourcing services. The Group reported 2011 global revenues of EUR 9.7 billion. Together with its clients, Capgemini creates and delivers business and technology solutions that fit their needs and drive the results they want. A deeply multicultural organization, Capgemini has developed its own way of working, the Collaborative Business Experience™, and draws on Rightshore ®, its worldwide delivery model.

Learn more about us at http://www.capgemini.com/

Rightshore® is a trademark belonging to Capgemini.

About HealthPrize Technologies:

HealthPrize Technologies provides an innovative approach to addressing the problem of medication non-adherence with an online and mobile-based program that is fun, educational and rewarding.  Patients are engaged and motivated by the HealthPrize system which utilizes gaming dynamics, behavioral economics and proven concepts from consumer marketing to engage and educate patients so they start and stay on prescribed medications.  

For more information, please visit http://www.healthprize.com/

Sources:

1Datamonitor, Addressing Patient Compliance: Targeted Marketing Driving a Shift in Focus From Acquisition to Retention. August, 2004.

Media Contact:

Andrea Orzehoski
Chandler Chicco Companies
212-462-8706
aorzehoski@chandlerchiccocompanies.com


'/>"/>
SOURCE HealthPrize Technologies
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Edison Pharmaceuticals Closes $20M Series F Financing
2. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
3. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
5. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
6. Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
7. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
8. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
9. Pharmaceutical Companies Donate $125,000 to Helmets to Hardhats Program
10. Sihuan Pharmaceutical Collaborates with NeuroVive to Develop Two Innovative Cardio-cerebral Vascular Products in China
11. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
Breaking Medicine News(10 mins):